Kura Oncology Reports Third-Quarter 2026 Financial Results and Corporate Update
Story updates
09:03:12 PM UTC
SquawkNews
KOMZIFTI® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient sta
Related stories
CoreWeave Q3 Revenue Jumps 168% to $3.66 Billion, Guidance Raised
CoreWeave reported Q3 revenue of $3.66 billion, up 168% and above expectations, and raised its full-year guidance to at least $13 billion.
M impact | EQUITY | Nov 10, 2026, 10:10 PM UTC
Costco Declares $30 Special Dividend, Reauthorizes Buyback
Costco declared a $30 special cash dividend and reauthorized its stock repurchase program.
M impact | EQUITY | Nov 10, 2026, 09:54 PM UTC
U.S. Stocks Fall on Inflation Data and AI Valuation Worries
The Dow fell 157.86 points, or 0.30%, to 52,231.89; the S&P 500 lost 29.01 points, or 0.38%, to 7,520.93. The report attributed the declines to hotter-than-expected inflation data
M impact | EQUITY | Nov 10, 2026, 09:53 PM UTC
Hyliion Reports Q3 Revenue of $7.5 Million, Raises 2026 Guidance to $18 Million
Hyliion reported third-quarter 2026 revenue of $7.5 million, up from $0.8 million a year earlier, and a net loss of $11.1 million. It raised full-year revenue guidance to approxima
M impact | EQUITY | Nov 10, 2026, 09:53 PM UTC
Invesco Reports Preliminary AUM of $2,453.50 Billion, Down 3.3%
Invesco said preliminary assets under management were $2,453.50 billion as of October 31, 2026, down 3.3% from the previous month-end.
M impact | EQUITY | Nov 10, 2026, 09:50 PM UTC
US API Gasoline Stock Change
L impact | EQUITY | Nov 10, 2026, 09:49 PM UTC